Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 8/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.34 |
| ▸ | LITAF | Q99732 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915477 | 0.95 | S1PR2 (0.52) | S1PR2TBK1NSD2 | |
| SCHEMBL23914857 | 0.91 | S1PR2 (0.43) | S1PR2TBK1BTKNSD2PIK3CD | |
| SCHEMBL23909045 | 0.88 | S1PR2 (0.51) | S1PR2 | |
| SCHEMBL23908838 | 0.86 | S1PR2 (0.58) | S1PR2 | |
| SCHEMBL23966573 | 0.84 | BTK (0.35) | S1PR2TBK1BTKNSD2PIK3CD | |
| SCHEMBL23908793 | 0.84 | S1PR2 (0.52) | S1PR2PIK3CD | |
| SCHEMBL23908822 | 0.84 | S1PR2 (0.54) | S1PR2 | |
| SCHEMBL23908868 | 0.83 | S1PR2 (0.61) | S1PR2 | |
| SCHEMBL23914714 | 0.83 | S1PR2 (0.60) | S1PR2BTKTNFLITAF | |
| SCHEMBL23915580 | 0.81 | S1PR2 (0.52) | S1PR2TNFLITAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885TBK1 2445/4885BTK 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.